-
Take over charity assistance to Junshi Bio-Treplimumab National Medical Insurance Implementation
Time of Update: 2021-05-03
Recently, at the melanoma branch of the second CSCO-Junshi Bio-Tumor Immunity Summit Forum, the anti-PD-1 monoclonal antibody drug Teriplizumab Injection (Tuoyi®) "Yilu is accompanied by Bethune·Tuoyi" The charity donation project" successfully completed its mission and the melanoma indications were included in the national medical insurance catalogue to celebrate the landing ceremony.
-
"Pharmaceutical Speed Reading Society" Zhong Suisui resigns from the post of chairman of the subsidiary of Yangshengtang
Time of Update: 2021-05-03
[March 23, 2021 / List of medical information] Zhong Sui Sui retires from the post of chairman of the subsidiary of Yangshengtang; AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine.
-
Hebo Pharmaceutical
Time of Update: 2021-05-03
On March 22, Harmonicare announced that its anti-CTLA-4 antibody HBM4003, an open phase 1 study for patients with advanced melanoma and other solid tumors in China, has completed the first patient medication.
-
How should traditional Chinese medicine companies spin off traditional Chinese medicines and transform them?
Time of Update: 2021-05-03
On March 22, Livzon Pharmaceutical announced that it plans to acquire 40% of Tianjin Tongrentang held by Tasly Holding Group as a financial investor for 724 million yuan.
-
National Health Commission: The key configuration of these medical equipment
Time of Update: 2021-05-03
The meeting requested that relevant departments in various regions should earnestly implement the spirit of the Central Deep Reform Commission meeting and the deployment requirements of the State Council, start with standardizing the behavior of medical subjects, increase the supervision and management of the behavior of medical institutions and medical staff, strengthen technological innovation, promote resource sharing, and make overall plans.
-
A complete analysis of the development of Shanghai's hospital drug market in 2020
Time of Update: 2021-05-03
Figure 3 2019-2020 Shanghai hospital drug market different levels of hospital market growth performance
Figure 5 The growth rate of different therapeutic areas in the Shanghai hospital drug market in 2020
-
Anlotinib sells for 4 billion yuan. How does China's biopharmaceuticals have a market value of 150 billion...
Time of Update: 2021-05-03
" According to statistics, in the four rounds of centralized procurement, China Biopharmaceuticals has won the bid for nearly 20 varieties, involving large varieties such as entecavir, engligliflozin, azacitidine, and large varieties with sales of more than 3 billion yuan in 2018.
-
The development of long-acting oral paclitaxel is terminated!
Time of Update: 2021-05-03
Compared with the capecitabine single-agent group, the tesitetaxel combination treatment group has grade 3 and above neutropenia (71.
The proportion of patients who discontinued treatment due to any adverse events in the tesitetaxel combination therapy group was 23.
-
Sub-Journal of "Nature": Protein degradation therapy attracts attention. It is expected that at least 15 models will enter...
Time of Update: 2021-05-03
In 2019, as Arvinas's oral small molecule PROTAC ARV-110 targeting the androgen receptor (AR) became the first protein degrading agent to enter clinical trials, this field has attracted more attention.
-
National Class 1
Time of Update: 2021-05-02
As the first domestic innovative epothilone anti-tumor drug independently developed by Huahao Zhongtian, the launch of Utidrolone provides an important new treatment option for Chinese patients with advanced breast cancer.
-
8 executives of well-known pharmaceutical companies resigned
Time of Update: 2021-05-02
However, since Zhao Yuexiang, Lin Jian, Wang Wei, Bai Zhiquan, Li Gang, Chen Guie, and Wang Weiqin are still serving in Hainan Haiyao after resigning from the aforementioned positions, the resignation of the above-mentioned senior executives will not have a significant impact on their normal business operations.
-
Tianjing Bio and ABL Bio announced the completion of TJ-L14B Phase 1 clinical trial in the United States...
Time of Update: 2021-05-02
On April 6, Tianjing Biotechnology and ABL Bio of South Korea jointly announced that the first US phase clinical study of the bispecific antibody TJ-L14B/ABL503 jointly developed by the two parties has completed the first patient administration.
-
All-round view of the CD30 target: ADC is a hit, but the red double antibody has no fruitful CAR...
Time of Update: 2021-05-02
Although CD30 has the characteristics of low expression in healthy cells and high expression in tumor cells, the performance of anti-CD30 drugs that enter clinical trials is not very satisfactory.
CD16A is the Fc receptor on NK cells, which can mediate IgG1 antibodies to kill tumor cells through ADCC.
-
"Pharmaceutical Speed Reading Club" Takeda Natpara is short of cefuroxime, arkamicin...
Time of Update: 2021-05-02
[April 7, 2021/Medical Information List] Revised instructions for cefuroxime and arkamicin; Microchip Biotech "Cioroni Capsules" launched Phase III clinical trials for small cell lung cancer; Hengrui HR19042 capsules were approved It is used to treat primary IgA nephropathy; Takeda's 100 microgram dose of Natpara will be cut off for 1 year.
-
Hengrui's 2020 financial report: revenue of 27.7 billion oncology drugs contributes 55% of PD...
Time of Update: 2021-05-02
Hengrui Medicine's revenue, net profit and R&D investment in the past 10 years (unit: 100 million yuan)
In terms of the internationalization of innovative drugs, a number of products have been approved to conduct global multi-center or regional clinical studies.
-
Innovation helps health China Pfizer won the "Best Partner Award"
Time of Update: 2021-05-02
Since entering the Chinese market for more than 30 years, Pfizer has always been committed to "becoming an important part of China's medical and health system" and has introduced more than 60 innovative drugs, covering five major areas including tumors, vaccines, anti-infection, inflammation and immunity, and rare diseases.
-
Nuocheng Jianhua's RTK inhibitor ICP-033 new drug research application was approved by the National Drug Administration...
Time of Update: 2021-05-02
Nuocheng Jianhua announced today that the company's new multi-target receptor tyrosine kinase (RTK) inhibitor ICP-033 New Drug Research (IND) application has been accepted by the National Medical Products Administration (NMPA).
ICP-033 is a class 1 innovative drug of Nuocheng Jianhua with global independent intellectual property rights.
-
Haisco HSK29116 obtained clinical approval in bulk
Time of Update: 2021-05-02
It is an oral Protac small molecule anti-tumor drug that can selectively block BTK kinase activity and interfere with B cell development by regulating signal pathways, thereby controlling various B cell malignant tumors.
-
Merck/Eisai’s “Immunity + Targeting” combination submits its first application in Japan
Time of Update: 2021-05-02
The results showed that Keytruda+Lenvima reached the primary endpoint (PFS) and key secondary endpoints (OS and ORR): In the intention-to-treat (ITT) study population, compared with the sunitinib group, the Keytruda+Lenvima treatment group was There were statistically significant and clinically significant improvements in PFS (HR=0.
-
How to Train Your Dragon: TG6002
Time of Update: 2021-05-02
The design concept of chemotherapeutic drugs like 5-FU is to simply kill tumor cells that replicate faster, but the actual working mechanism is more complicated.
Therefore, in addition to selectively killing tumor cells, oncolytic viruses have a more important purpose for immune activation.
